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Abstract
Background: Hepatitis C affects over 185 million people around the world. This silent disease is responsible for up
to 700,000 deaths per year. Despite the scientific revolution in diagnosis and treatment, hepatitis C control remains
a huge challenge due to the cost of effective medications.
In response to the global outcry of hepatitis epidemic and the need to improve the nation’s public health response,
the Ministry of Health of Brazil revolutionized hepatitis C treatment by incorporating highly effective drugs that can be
accessed through sustainable and universal means.
Discussion: This paper describes the unique process of implementing evidence-informed policy to respond to
hepatitis C epidemic through the update of hepatitis C treatment in Brazil based on the estimate of disease
prevalence, current international guidelines, and the cost-effectiveness impact in the Brazilian Unified Health
System. Through a debate of an experience report, the authors underlie the strategic plan implemented according to
the situation analysis that emphasized the need to improve its current response over a relatively short-term period. The
comprehensive response is detailed comprising three main objectives: improve treatment outcomes by evaluating and
incorporating new and effective medications at a sustainable price; elaborate on clinical guidelines to treat hepatitis C
patients; and develop awareness and diagnosis campaigns targeted at the population of interest. In this scenario, Brazil
was able to obtain an unprecedented discount for a high-medium income country; provided treatment to more than
7000 individuals in the last 2 months of 2015; and expects to treat 38,000 new patients in 2016.
Summary: The remarkable process applied in Brazil was developed according to epidemiological data and scientific
evidence, and it was motivated by the engagement of the country in the Sustainable Development Goals, which may
inspire other developing countries to identify ways to achieve these goals by 2030.
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Background
Over 185 million people are infected with the hepatitis
C virus (HCV) worldwide [1, 2]. HCV infection is usu-
ally asymptomatic, with symptoms occurring mostly at
advanced stages of the disease. Its late diagnosis contrib-
utes to transmission of the disease and its associated
high mortality. It is estimated that 350,000 to 700,000
deaths could occur annually exclusively due to HCV
infection [1, 3].
There were no means of diagnosing HCV infection
until early 90’s, when tests finally became available and
routinely performed in blood banks [4]. Such restriction
of technology in diagnosis was also common to thera-
peutics, which until recently was mostly acknowledged
by poor treatment adherence and efficacy and high rates
of adverse events.
Recent scientific developments have granted health
professionals and patients a new opportunity to defeat
hepatitis C [5, 6]. Improved understanding of the virus,
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as well as the research and development of new medica-
tions, has resulted in new and effective treatments and a
promising pipeline for years to come [7].
Unfortunately, such success is reserved for those who
can afford expensive new treatments and is beyond the
reach of developing countries, which constitute the ma-
jority of the world’s population. The global scientific
community and civil society have objected to the finan-
cial restrictions imposed on the right to health [8].
To improve the nation’s public health response, the
Ministry of Health (MoH) of Brazil decided to act and
to revolutionize hepatitis C treatment by incorporating
highly effective drugs with sustainable and universal ac-
cess, according to the principles of the country’s Unified
Health System (SUS)–universality, integrality and equity.
The division responsible for this feat was the Depart-
ment of STI, AIDS and Viral Hepatitis (DDAHV). From
the outset, the Health Minister’s Office, the Secretariat
of Health Surveillance (SVS), the Secretariat of Science,
Technology and Strategic Inputs (SCTIE), the Brazilian
Health Surveillance Agency (ANVISA), organized civil
society and the scientific community, supported the ini-
tiative. This joint effort resulted in significant positive
changes to public health policy in Brazil.
Different countries need specific strategies to address
viral hepatitis, given the variability in epidemiology and
public health infrastructure. However, we understand
that many countries willing to fight to control hepatitis
C, as a public health problem (according to the Sustain-
able Development Goals), would benefit from the stra-
tegic thinking applied by the MoH of Brazil during this
next phase of hepatitis C assistance.
This paper aims to describe the unique process of
implementing evidence-informed policy to respond to
hepatitis C epidemic through the update of hepatitis C
treatment in Brazil including an interferon-free therapy,
with the direct-acting antiviral treatment, based on the
up-to-date estimate of disease prevalence in the country,
current international guidelines, and cost-effectiveness
impact in SUS.
Discussion
At first, the MoH of Brazil in partnership with the Univer-
sity of Sao Paulo Medical School developed a mathemat-
ical model to estimate the number of people living with
chronic hepatitis C [9]. The mathematical model was per-
formed using figures from the most recent 12 years from
two major national databases: the Information System on
Diseases of Compulsory Declaration (SINAN) and the
Brazilian System of Transplants (SNT/MS) [10].
The model estimated that 1.4 to 1.7 million people are
chronically infected with HCV in Brazil. Recent figures
from the national datasets (2008–2014) elucidated that
the population aged 40 and older is the group most af-
fected by hepatitis C. These people were most likely in-
fected before 1993, when blood safety was not optimal
and injection drug use was still a public health issue, and
they were diagnosed 15 to 30 years later (Fig. 1) [11, 12].
Further development of the mathematical model, it
was estimated that to control hepatitis C the country
would not only need to increase the treatment effective-
ness from 50 to 90 % chance of cure but also make
considerable efforts to expand treatment numbers, in-
creasing from an average of 15,000 treatments to 45,000
treatments per year [9, 11]. Such findings have raised
concerns about the extent of investment required to
control hepatitis C, and provided insight regarding the
ongoing progression of undetected disease, the likeli-
hood of accumulated comorbidities, and the develop-
ment of cirrhosis and hepatocellular carcinoma—greatly
affecting the health system in the future.
So next, the DDAHV assessed care and treatment indi-
vidual registers through national databases of hospitali-
zations due to hepatocellular carcinoma, viral hepatitis
and liver transplants. Despite modern advances in more
complex medical care and significant improvements in
Fig. 1 Hepatitis C cases according to age and gender, Brazil, 2008–2014
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waiting lists and liver transplant numbers, over the last 7
years, hospitalizations due to hepatocellular carcinoma
increased greatly, reaching an average case fatality rate
of approximately 23 %–probably as a result of the high
prevalence of chronic hepatitis C (Fig. 2).
Additionally, the DDAHV evaluated the previous
treatments provided by the MoH of Brazil through SUS
since the formulation of the National Plan for Viral
Hepatitis in 2002. Past treatments have provided unsatis-
factory results; rates of cure were low, and the available
therapies did not include a significant share of patients,
such as those coinfected with HIV/HCV or presenting
advanced liver disease with clinical decompensation [13].
Nearly 50,000 people who have been treated but not
cured were waiting for a suitable therapy.
This situation analysis determined that Brazil would
need to improve its current response to hepatitis C epi-
demic over a relatively short-term period. In this con-
text, the MoH of Brazil defined a strategic plan to fulfill
three main objectives: 1) improve treatment outcomes
by evaluating and incorporating new and effective medi-
cations at a sustainable price; 2) elaborate on clinical
guidelines suitable for all physicians willing to treat
hepatitis C patients; and 3) develop awareness and diag-
nosis campaigns targeted at the population of interest
(people aged 40 years or older).
As the first action, the MoH of Brazil appointed by re-
quest a national steering committee on viral hepatitis
[14]. This working group comprised representatives of
research institutes, higher education institutions, health
professionals in charge of the care and treatment of viral
hepatitis, and organized civil society. The committee
supported the design of the new National Clinical
Guidelines, and suggested improvements regarding
diagnosis, staging and treatment of viral hepatitis for the
universal healthcare system in Brazil.
In order to make evidence-based update of hepatitis
C treatment in Brazil, the DDAHV reviewed the evi-
dences from international societies and organizations
recommendations [15–17]. The DDAHV also per-
formed a review of the available scientific literature
on hepatitis C therapy. The review included Clinical
Conference annals, Clinical Trials (I, II, III, IV), Consensus
Development Conference, Evaluation Studies, Guidelines,
Meta-Analysis, Multicenter Studies, Practice Guidelines,
Randomized Controlled Trials, Reviews, and Systematic
Reviews, published on the last 5 years. The evidences were
classified according to the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
system, and submitted to the steering committee for
approval.
The bibliographical review submitted for committee
evaluation resulted in the selection of three direct-acting
antiviral drugs for the national guidelines: daclatasvir,
simeprevir and sofosbuvir. Since these drugs had never
been tested against each other in clinical trials, the
DDAHV ensued by filtering the collection of scientific
literature and deconstructing it in cohorts according to
the type of study (phase number or real-life); character-
istics of the population (presence of coinfection HIV/
HCV and severity of disease); HCV genotype (1 to 4);
experimented treatment regimen; duration of treatment;
and sustained virologic response 12 or 24 weeks after
completion of antiviral therapy.
With the objective to implement a sustainable and cost-
effective treatment in the public health system, based on
estimates of current and future economic impact, the
MoH of Brazil performed continuous negotiations with
Fig. 2 Hospitalizations, deaths and case fatality rates due to liver cancer, Brazil, 2008–2014
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pharmaceutical companies regarding the prices of the
proposed medications that would be featured in the
new clinical guidelines in substitution of interferon.
The pharmaceutical companies were given 6-month
period to present suitable prices through an official
commercial proposal, with the chance to submit com-
mercial proposals featuring a >90 % discount on
international market prices, and to update any reports
on the safety and efficacy of their products.
Once the approved commercial proposals were fin-
ished and officially registered in October 2014, different
segments of the MoH of Brazil evaluated the documents
internally. The ANVISA, responsible for the formal ap-
proval of new medicines in the Brazilian health system,
gave priority for analysis of safety and efficacy of the
new medications, evaluated and approved all three drugs
by March 2015. Later, the National Committee for
Health Technology Incorporation (CONITEC) evaluated
and approved the implementation of the new therapies
in SUS after the official public consultation.
The intense negotiation with pharmaceutical com-
panies provided Brazil with an unprecedented dis-
count for a high-medium income country, achieving
more than 90 % discount over international prices
and 20 % over Brazilian reference charts for prices,
resulting a final price of under US$ 10,000.00 for 12
weeks of treatment with two oral drugs. Thus, the
MoH of Brazil was able to provide treatment to more
than 7000 people in the last 2 months of 2015 based
on the new guidelines, and it is expected that the
MoH will treat at least 38,000 new patients in 2016.
In the meanwhile, the elaboration of the national clin-
ical guidelines focused on eliminating obstacles to access
to care and treatment, such as expanding indications for
immediate antiviral treatment of hepatitis C to patients
with mild to severe liver fibrosis. Patients with coinfec-
tion with HIV, chronic kidney disease, malignant neo-
plasms of lymphoid and blood-forming organs, lichen
planus, glomerulonephritis and having undergone solid
organ transplant were also granted immediate access to
the new antiviral treatment.
The national guidelines were also meant to provide
minimum standards of care with routine medical ap-
pointments and tests and included less invasive alterna-
tives for the evaluation of liver fibrosis, such as the use
of Aspartate Aminotransferase to Platelet Ratio Index
(APRI) and Fibrosis-4 (FIB4) scores or elastography,
when liver biopsy is not recommended or is simply un-
available. This approach had already been featured in
the international recommendations [17], but it had never
been fully adapted to the Brazilian context. The purpose
of these positive changes were to increase accessibility to
hepatitis C treatment, especially for those living in re-
mote areas or locations that lack specialized physicians,
and contribute to the cost effectiveness of the health sys-
tem, decreasing the numbers of unnecessary tests and
optimizing care.
In addition, the molecular biology tests routinely per-
formed to treat hepatitis C were reviewed and supple-
mented with strategic data inputs. This process ensures
that the country will have one of the most complete cen-
tralized databases in the world, created by the largest
real-life cohort for new hepatitis C treatment. Further-
more, it will have relevant data that may help influence
current and future pharmaceutical advances.
So at last, the SCTIE and the CONITEC evaluated the
proposed clinical guidelines and the economic impact
estimates [18] and conveyed all updated recommenda-
tions through public consultation to ensure social par-
ticipation, transparency and accountability in the health
system administration.
In October 2015, Brazil began providing interferon-free
treatment for hepatitis C using combinations of sofosbu-
vir + daclatasvir or sofosbuvir + simeprevir. The new clin-
ical guidelines enhances treatment access by including
recognized non-invasive technologies as substitutes for
liver biopsy when necessary, amplifying the opportunity to
achieve the criteria for starting the treatment.
Finally, the DDAHV strengthened public awareness
and conducted a new diagnosis campaign in order to de-
bunk the myth that hepatitis C is a chronic incurable
disease, and sought to reach the target population
through different media. It called for testing those 40
years or older and featured themes regarding past expos-
ure to drugs, unsafe sex, tattoo and medical procedures
before 1993, such as surgeries and blood products trans-
fusion, as means to reach the population most at risk of
having contracted the hepatitis C virus.
The scientific community and national civil society
promptly accepted and supported the successful cam-
paign. Before the first half of 2015, the MoH of Brazil
had already distributed the same amount of rapid tests
for hepatitis C diagnosis distributed in 2014, and com-
mitted to an acquisition of over 8 million rapid tests for
the following months.
Conclusions
Based on the need to refine and to improve the history
of committing to the provision of universal access to
hepatitis C treatment in Brazil during the last 15 years
[4], this remarkable process of evidence-informed policy
making–which involved many different actors–changed
the Brazilian Clinical Guidelines for Hepatitis C in 2015.
Brazil revolutionized the response to hepatitis C epi-
demic motivated by the nation’s engagement in the Sus-
tainable Development Goals.
The MoH of Brazil managed to fit this response strat-
egy in a 16-month interval by working the momentum
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of competitive pharmaceutical development scenario
to its favor, rising up the bars for epidemiology data
analysis, increasing pace in technology evaluation and
narrowing communications with scientific community
and organized civil society. The standardization of
care for hepatitis C also facilitates the flow of treatments,
cuts unnecessary costs in laboratory monitoring and facili-
tates evaluation of incorporated technologies and clinical
guidelines. The commitment of different sectors in
the MoH of Brazil, the support of all members of the
steering committee, the impressive mobilization of
civil society, and the flexibility of pharmaceutical
companies in the negotiation were crucial for the ad-
vancement of this process.
Tackling a public health problem demands full com-
mitment and thorough situation analysis with consider-
able financial resources for any future policy changes.
Such requirements are unlikely to be met simultaneously
in every scenario, particularly in viral hepatitis. However,
the experience gathered by those countries who were
successful in planning and implementation can drastic-
ally reduce expenses and invested time.
This comprehensive study of the Brazilian experience
allows one to understand that such steps secured means
for market scenario development: epidemiology analysis
and national guidelines provided numbers of future
treatments and effective team work allowed good timing
for strategy implementation, thus changing such public
health policy changes for viral hepatitis into a win-win
condition for any of the parties involved, especially when
there is the right to universal access to health. As policy
makers, we should do our homework and constantly
think out of the box, keeping negotiation channels inter-
esting and open as much as possible.
The national decision was affordable, important and
sustainable, and the MoH of Brazil will be able to in-
spire other developing countries to identify ways to
achieve this specific goal of the Sustainable Develop-
ment Goals by 2030.
To sum it up, there is a moment when the clear un-
derstanding of health as human right clashes with the
misunderstanding that market based scenarios should be
restricted to individual or corporate purchases. Though
sometimes rather questionable and far from ideal, mutu-
ally beneficial arrangements are quite possible for public
health and capitalism. Given the estimates of disease
burden, hepatitis C related events case-fatality rates and
age of the affected population, it is clear that neither
Brazil nor pharmaceutical companies could wait for their
own silver bullets any longer and perhaps they should
share silver medals instead.
Rest assured, whatever future negotiations hold for
Brazil and other countries, nobody will wait much lon-
ger for the affordable treatments for hepatitis C.
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